Actively Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Led by Bristol-Myers Squibb · Updated on 2026-05-07
240
Participants Needed
11
Research Sites
168 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer
CONDITIONS
Official Title
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
- Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
- In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
You will not qualify if you...
- Participants must not have any untreated CNS metastases.
- Participants must not have an active, known or suspected autoimmune disease.
- Participants must not have had a prior organ or tissue allograft.
- Other protocol-defined Inclusion/Exclusion criteria apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Local Institution - 0011
Detroit, Michigan, United States, 48201
Not Yet Recruiting
2
Local Institution - 0026
Buffalo, New York, United States, 14263
Not Yet Recruiting
3
Duke Cancer Institute
Durham, North Carolina, United States, 27710
Actively Recruiting
4
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
5
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
6
Local Institution - 0001
Rozzano, Milano, Italy, 20089
Not Yet Recruiting
7
Local Institution - 0020
Hirakata, Osaka, Japan, 573-1191
Not Yet Recruiting
8
Local Institution - 0018
Chuo-ku, Tokyo, Japan, 104-0045
Not Yet Recruiting
9
Local Institution - 0023
Timișoara, Timiș County, Romania, 300239
Not Yet Recruiting
10
Local Institution - 0003
Craiova, Romania, 200347
Not Yet Recruiting
11
Local Institution - 0009
Madrid, Spain, 28041
Not Yet Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here